Elacestrant
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Elacestrant |
| DrugBank ID | DB06374 |
| Brand Names (EU) | Orserdu |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 92.50% |
Approved Indication (EMA)
Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | amenorrhea (disease) | 92.50% | DL |
| 2 | bone Paget disease | 86.81% | DL |
| 3 | multiple endocrine neoplasia | 85.85% | DL |
| 4 | primary cutaneous T-cell lymphoma | 84.71% | DL |
| 5 | seborrheic dermatitis | 83.32% | DL |
| 6 | familial adrenal hypoplasia with absent pituitary luteinizing hormone | 82.91% | DL |
| 7 | candidiasis | 82.04% | DL |
| 8 | Leydig cell hypoplasia due to LH resistance | 81.79% | DL |
| 9 | hypogonadotropic hypogonadism with or without anosmia | 81.67% | DL |
| 10 | 46,XY disorder of sex development due to impaired androgen production | 81.65% | DL |
| 11 | seborrheic keratosis | 81.53% | DL |
| 12 | adrenocortical insufficiency | 81.34% | DL |
| 13 | PAGOD syndrome | 81.28% | DL |
| 14 | vulvar inverted follicular keratosis | 80.71% | DL |
| 15 | 46,XY disorder of sex development | 80.60% | DL |
| 16 | renin-angiotensin-aldosterone system-blocker-induced angioedema | 80.31% | DL |
| 17 | dermoid cyst of ovary | 78.75% | DL |
| 18 | spinal cord dermoid cyst | 78.63% | DL |
| 19 | cystic teratoma | 78.60% | DL |
| 20 | disease of orbital part of eye adnexa | 78.52% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.